Welcome to the only official website of safeglp www.safeglp.com

SAFE Pharmaceutical Research Institute and PerkinElmer Collaborative Innovation Center of New Drug Evaluation

2020-01-17
SAFE Pharmaceutical Research Institute and PerkinElmer Collaborative Innovation Center of New Drug Evaluation(Collaborative Innovation Center), using the experts in innovative medicine research and technical resources of SAFE Pharmaceutical Research Institute, combined with the top international research and development equipment provided PerkinElmer, has successfully completed a number of medical research and development experiments, including anti-tumor research, cell therapy research, and nerve-related disease research, especially in the CAR-T study, which has achieved remarkable results.

At present, CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies while it faces more severe challenges in the treatment of solid tumors. The reason is mainly related to the high heterogeneity of solid tumors and the complex micro-environment of tumor immune suppression. Therefore, how to break through the treatment of solid tumors is one of the focal points of the CAR-T study, and it is also a hope of all cancer patients. Recently, the Collaborative Innovation Center has completed a number preclinical evaluations of new CAR-T  preparation of solid tumors, and has achieved encouraging results. Among them, a new type of CAR-T preparation is particularly effective in the treatment of human kidney cancer cell line 786O-CD19-GFP-Luc subcutaneous transplantation tumor model. In vivo imaging of small animals was performed at 7 and 42 days after a single intravenous injection of the CAR-T formulation.

In vivo imaging of small animals was performed at 7 and 42 days after a single intravenous injection of the CAR-T formulation. The results showed that after 7 days of treatment, the tumors of the many mice in the treatment group disappeared, and no recurrence was observed at 42 days (Figs. 1 and 2). This result suggests that the new CAR-T formulation has a promising prospect in the field of solid tumors therapy

Figure 1 PerkinElmer’s IVIS Lumia III Bio-Real in vivo imaging equipments


SAFE Pharmaceutical Research Institute-PerkinElmer Collaborative Innovation Center of New Drug Evaluation

SAFE Pharmaceutical - PerkinElmer New Drug Evaluation Collaborative Innovation Center, owns international advanced equipment such as IVIS Lumina III imaging system. By bioluminescence or fluorescent labeling, cells, proteins, antibodies, nucleic acids and other drug molecules can be labeled, and the highly sensitive IVIS Lumina III system can be used to study the biological response and targeted distribution of the subject in vivo. In the non-invasive situation, real-time observation of tumor growth and metastasis in animals, distribution and metabolism of materials or drugs in the body, gene expression and other biological processes have been widely used in basic research and drug research and development. At present, the Collaborative Innovation Center has established a one-stop pre-clinical evaluation technology platform for anti-tumor drugs, CAR-T therapy, stem cell therapy, gene therapy drugs and immunotherapeutics. In the majority of scientific research personnel and drug research and development companies to provide high quality and efficient services.


Tel

Mr. Du(18800003391)
E-mail:dujie@safeglp.com

Mr. Zhang(17801093678)
E-mail:zhangxiaolei@safeglp.com

Prev:

WeChat